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EpilepsyWe report a case of sustained ventricular tachycardia following the initiation of lacosamide as adjunctive ep-
ilepsy treatment. A 49-year-old male with intractable frontal lobe seizures experienced severe ventricular
tachycardia following the addition of 400 mg lacosamide to his existing regimen of carbamazepine,
lamotrigine, clonazepam, and valproate. The tachycardia occurred during a cardiac stress test; stress tests
prior to initiation of lacosamide were normal. Conduction defects, including QRS prolongation, persisted dur-
ing hospitalization until lacosamide was discontinued. The patient had no prior history of cardiac arrhythmia
but did possess cardiac risk factors, including hypertension, hypercholesterolemia, and low heart rate vari-
ability. This case represents one part of a growing body of literature suggesting a link between arrhythmia
and use of lacosamide, which enhances slow inactivation of sodium channels in both the brain and the
heart. We believe further study may be necessary to assess the safety of lacosamide in epilepsy patients
with cardiac risk factors.
© 2012 The Authors. Published by Elsevier Inc.Open access under CC BY-NC-SA license.1. Introduction
Sudden unexplained death in epilepsy (SUDEP) is a leading cause
of death among patients with severe, refractory epilepsy, accounting
for between 10% and 50% of all deaths in these patients [1]. Several
SUDEP risk factors have been identiﬁed, including polytherapy with
a number of antiepileptic drugs (AEDs) [2]. However, the relationship
between AED use and SUDEP remains unclear because the mecha-
nism of SUDEP is poorly understood [1]. Data on the relationship be-
tween AED use and cardiac arrhythmias are particularly limited [3].
Much of the data linking AED use to arrhythmia and SUDEP are de-
rived from small case series and video-telemetry studies in patients
undergoing video-telemetry, where tachycardia, bradycardia, and
conduction abnormalities (prolongation of the QT interval) may
occur during and after seizures [3–5]. The present case describes se-
vere arrhythmia in a patient treated with lacosamide, a sodium
channel blocker with a novel mechanism: enhancement of sodiumicine, Department of Neurology,
.
gio).
Inc. Open access under CC BY-NC-SA lchannel slow inactivation. This case is one of several recent cases
linking lacosamide to severe cardiac events [6,7]. Taken together,
these reports indicate the need for a more authoritative study of
lacosamide and cardiac risk.
Lacosamide [(R)-2-acetamido-N-benzyl-3-methoxproionamide]
is a novel antiepileptic drug that enhances slow inactivation of
voltage-gated sodium channels [8]. It was approved as adjunctive
therapy for epilepsy by the FDA in October 2008 [9]. Preclinical
and clinical trials suggest that lacosamide acts upon both neurons
and the heart and may increase the risk of cardiac arrhythmias
[9]. In studies of isolated canine Purkinje ﬁbers, lacosamide re-
duces action potential duration and maximal upstroke velocity in
a dose-dependent manner [8]. Moreover, in human myocytes,
therapeutic levels of lacosamide inhibit SCN5A, a cardiac sodium
channel [8]. In-vivo canine studies conﬁrm that lacosamide acts
as a cardiac depressant, causing decreased systolic left ventricular
pressure, decreased velocity of pressure change, reduced cardiac
output, and transient increases in PR interval and QRS complex du-
ration [8].
A Phase III study of lacosamide in diabetic peripheral neuropa-
thy found that lacosamide was associated with cardiac conduction
defects (AV block) in 0.5% of subjects and atrial ﬁbrillation in 0.5%
versus no cardiac events in the placebo cohort [9]. In Phase III
epilepsy trials, conduction defects (AV block) occurred in 0.4%
of lacosamide subjects versus none for placebo [9–11]. Post-
marketing studies have observed a small median increase in PR
interval of patients taking lacosamide [10,11]. Moreover, recenticense.
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disturbances and arrhythmias [6,7]. We report a similar case of ven-
tricular tachycardia associated with initiation of adjunctive lacosamide
treatment.2. Report of a case
A 49-year-old male with severe drug-resistant complex partial and
generalized tonic-clonic seizures of frontal lobe onset was placed on
400 mg/day lacosamide to complement his existing AED regimen of
carbamazepine, lamotrigine, clonazepam, and valproate. The patient
had undergone a left orbital–frontal craniotomy in 1989 that failed to
control his epilepsy. Moreover, the patient's seizures failed to improve
with a number of AEDs, including phenytoin and levetiracetam. The pa-
tient had no prior history of cardiac events but was on atorvastatin,
valsartan, and triamterene for well-controlled hypertension and hyper-
cholesterolemia. In addition, the patient had low heart rate variability
(HRV), detected during a clinical trial of n−3 fatty acids for epilepsy.
Heart rate variability has been associated with a higher risk of sudden
cardiac death in healthy patients [12].
Prior to the initiation of lacosamide, the patient had undergone two
cardiac treadmill stress tests while taking his normal AED regimen and
experienced no recorded cardiac arrhythmias on electrocardiography
(ECG). The patient did not report any signiﬁcant lifestyle or health
changes following these two stress tests that may have contributed to
a cardiac event. Of note, no arrhythmias were reported during prior sei-
zures captured during video-EEG monitoring, and multiple Holter ECG
monitoring for a clinical trial also failed to identify any arrhythmia.
Four months after initiating lacosamide, during a third treadmill stress
test, the patient developed sustained ventricular tachycardia (Fig. 1).
The ventricular tachycardia resolved acutely after cessation of the
stress test, and no cardiac enzyme elevation was noted to suggest myo-
cardial infarction as the cause. He was admitted to Glendale Medical
Center emergently and underwent continuous cardiac ECG telemetry.
During the hospitalization, his physicians rapidly lowered the lacosamide
dose by 100 mg/dayuntil lacosamide termination. During hospitalization,
the ECG demonstrated ﬁrst-degree AV block, posterior left fascicular
block, and severe widening of the QRS complex, but following dis-
continuation of lacosamide, the patient's ECG immediately returned
to baseline (Fig. 2). An automatic deﬁbrillator was implanted withFig. 1. Electrocardiography recording from the patient's cardiac stress test wan event recorder. Over one year after termination of lacosamide,
the patient had reported no cardiac complications, and the event
monitor has not identiﬁed any episodes of ventricular tachycardia
or arrhythmias.3. Discussion
We report a patient with drug-resistant epilepsy who suffered
sustained ventricular tachycardia and a ventricular conduction dis-
turbance during a stress test while exposed to adjunctive lacosamide
as part of his AED regimen. Though ventricular tachycardia resolved
spontaneously, the conduction defects resolved only after discontinu-
ation of lacosamide following which all cardiac conduction abnormal-
ities resolved. Extended implantable cardiac monitor failed to identify
any cardiac arrhythmias after the lacosamide termination. The onset
of the arrhythmia during the period while the patient was exposed
to lacosamide, the acute abnormality of cardiac conduction which
did not resolve until lacosamide was discontinued, and the absence
of arrhythmia in the long-term follow-up provide evidence for a possi-
ble role of lacosamide in the patient's ventricular tachycardia.
The case is complicated by the patient's concurrent treatment with
several AEDs, including two sodium channel blockers, lamotrigine and
carbamazepine. Lamotrigine has been associated with several cases of
SUDEP, while carbamazepine has been associated with a number of ar-
rhythmias [4,13]. Both drugs may exert pro-arrhythmic inﬂuence by
inhibition of IKr, a cardiac potassium channel, which lacosamide does
not affect [13–16]. However, this mechanism of action remains contro-
versial, largely because prolonged QTc, a consequence of IKr inhibition,
has not been observed with lamotrigine or carbamazepine in humans
[4,14,15].
Lacosamide, carbamazepine, and lamotrigine all inhibit the cardiac so-
dium channel SCN5A in a concentration-dependent manner [8,15–17].
Disruption of the SCN5A channel has been associated with severe ar-
rhythmia, including ventricular tachycardia, in patients with Brugada
syndrome, a channelopathy associated with an increased risk of ventric-
ular tachycardia and sudden death [18]. Unfortunately, a direct compari-
son of SCN5A inhibition curves for lacosamide, carbamazepine, and
lamotrigine cannot bemade because of the limited preclinical lacosamide
data available [7]. In-vitro lacosamide elicits 10–20% SCN5A inhibition at
upper therapeutic concentrations, so it is reasonable to believe thathile taking lacosamide 400 mg/day, illustrating ventricular tachycardia.
Fig. 2. Electrocardiogram after stabilization of ventricular tachycardia. The ECG demonstrated ST elevation, early repolarization, borderline AV conduction delay, and left posterior
fascicular block.
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arrhythmia [8]. Moreover, lacosamide is believed to inhibit SCN5A
by enhancing slow inactivation, a novel mechanism [8]. Several
SCN5A mutations that amplify intermediate or slow inhibition have
been associated with Brugada syndrome and sudden death [18–21].
Lacosamide's mechanism may complement that of other sodium
blockers and amplify the cardiac effects associated with them
[13–15].
This case report provides additional evidence for a possible role of
lacosamide in cardiac arrhythmias in patients with drug-resistant ep-
ilepsy. The lethal potential of the arrhythmia (sustained ventricular
tachycardia) is of particular concern. The timing of the ventricular
tachycardia after initiation of lacosamide and resolution after its dis-
continuation suggests a possible pro-arrhythmic role for lacosamide.
It is our hope that there will be further investigation into the cardiac
effects of lacosamide and the role of slow sodium inactivation in ar-
rhythmias in patients with epilepsy.
References
[1] Tomson T, Walczak T, Sillanpaa M, Sander JWAS. Sudden unexpected death in
epilepsy: a review of incidence and risk factors. Epilepsia 2005;46:54-61.
[2] Nilsson L, Farahmand BY, Persson PG, Thiblin I, Tomson T. Risk factors for sudden
unexpected death in epilepsy: a case–control study. Lancet 1999;353:888-93.
[3] Tomson T, Kenneback G. Arrhythmia, heart rate variability, and antiepileptic
drugs. Epilepsia 1997;38:S48-51.
[4] Saetre E, Abdelnoor M, Amilie JP, et al. Cardiac function and antiepileptic drug
treatment in the elderly: a comparison between lamotrigine and sustained-
release carbamazepine. Epilepsia 2009;50:1841-9.
[5] Surges R, Scott CA, Walker MC. Enhanced QT shortening and persistent tachycar-
dia after generalized seizures. Neurology 2010;74:421-6.[6] DeGiorgio CM. Atrial ﬂutter/atrial ﬁbrillation associated with lacosamide for
partial seizures. Epilepsy Behav 2010;18:322-4.
[7] Nizam A, Mylavarapu K, Thomas D, et al. Lacosamide-induced second-degree
atrioventricular block in a patient with partial epilepsy. Epilepsia 2011;52:153-5.
[8] Beyreuther BK, Freitag J, Heers C, et al. Lacosamide: a review of preclinical
properties. CNS Drug Rev 2007;13:21-42.
[9] UCB, Inc. Vimpat prescribing information; April 2011.
[10] Rosenfeld W, Fountain NB, Kaubrys G, et al. Abstract: lacosamide: an interim
evaluation of long-term safety and efﬁcacy as oral adjunctive therapy in subjects
with partial-onset seizures. Epilepsia 2007;48(Suppl. 6):318.
[11] Chung S, Sperling M, Bilton V. Lacosamide as adjunctive therapy for partial-onset
seizures: a randomized controlled trial. Epilepsia 2010;51:958-67.
[12] Stein PK, Kleiger RE. Insights from the study of heart rate variability. Annu Rev
Med 1999;50:249-61.
[13] Aurlien D, Tauboll E, Gjerstad L. Lamotrigine in idiopathic epilepsy — increased
risk of cardiac death? Acta Neurol Scand 2007;115:199-203.
[14] Danielsson BR, Lansdell K, Patmore L, Tomson T. Effects of the antiepileptic drugs
lamotrigine, topiramate and gabapentin on hERG potassium currents. Epilepsy
Res 2005;63:17-25.
[15] Danielsson C, Azarbayjani F, Sköld AC, Sjögren N, Danielsson BR. Polytherapy with
hERG-blocking antiepileptic drugs: increased risk for embryonic cardiac arrhythmia
and teratogenicity. Birth Defects Res A Clin Mol Teratol 2007;79:595-603.
[16] Dixon R, Job S, Oliver R, et al. Lamotrigine does not prolong QTc in a thorough
QT/QTc study in healthy subjects. Br J Clin Pharmacol 2008;66:396-404.
[17] Harmer AR, Valentin J-P, Pollard CE. On the relationship between block of the cardiac
Na+ channel and drug-induced prolongation of the QRS complex. Br J Pharmacol
2011;164:260-73.
[18] Antzelevitch C, Brugada P, Borggrefe M, et al. Brugada syndrome: report of the
second consensus conference. Circulation 2005;111:650-70.
[19] VeldkampMW, Viswanathan PC, Bezzina C, Baartscheer A, Wilde AA, Balser JR. Two
distinct congenital arrhythmias evoked by a multidysfunctional Na+ channel. Circ
Res 2000;86:e91-7.
[20] Wang DW, Makita N, Kitabatake A, Balser JR, George AL. Enhanced Na+ channel
intermediate inactivation in Brugada syndrome. Circ Res 2000;87:e37-43.
[21] Casini S, Tan LH, Bhuiyan ZA, et al. Characterization of a novel SCN5A mutation
associated with Brugada syndrome reveals involvement of DIIIS4–S5 linker in
slow inactivation. Cardiovasc Res 2007;76:418-29.
